Evaluation, Comparison and Correlation of the Disease Activity and Damage Index among Patients of SLE with Healthy Controls through Echocardiography
Keywords:
SLE, Systemic lupus erythematosus, Echocardiography, Lupus nephritis, cardiovascular complications, valvular heart diseaseAbstract
OBJECTIVE: To assess and compare echocardiographic findings in SLE patients with healthy controls and their correlation with disease activity and damage index.
METHODOLOGY: This cross-sectional study was undertaken in the Department of Medicine, Civil Hospital Karachi, an affiliated hospital of Dow University of Health Sciences (DUHS) Karachi, Pakistan, from January to July 2023. Forty-one patients with SLE and Thirty-nine healthy controls were enrolled, undergoing echocardiographic analysis for cardiovascular complications with the clinical and biochemical profile. Statistical differences among groups were assessed using the Chi-square test for qualitative variables and the independent sample t-test for quantitative variables. The correlation between disease severity and cardiovascular events was determined by Pearson correlation. P ? 0.05 was measured as statistically significant.
RESULTS: The most common valvular abnormality was mitral regurgitation (48.7%), then tricuspid regurgitation (21.9%), aortic regurgitation (17.7%), mitral stenosis (2.4%) and mitral valve prolapse (4.8%) in SLE, Left ventricular internal diameter end diastole [p 0.001], Intraventricular septal wall thickness, and end-diastolic left ventricular internal diameter end-systole [p 0.002] were found statistically significant among the groups. Left ventricular posterior wall end-diastole [p < 0.00001] and pulmonary artery systolic pressure [p < 0.00001] were also substantial among groups. Lupus nephritis positively correlated to ejection fraction (r=0.00013, p 0.56).
CONCLUSION: Cardiovascular complications are frequently reported in SLE, as assessed by echocardiographic findings. SLE severity is related to echocardiographic changes, and SLE with secondary Antiphospholipid syndrome (APS) significantly affects renal, haematological, and echocardiographic parameters.
References
Justiz Vaillant AA, Goyal A, Varacallo M. Systemic Lupus Erythematosus. [Updated 2023 Aug 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535405/
Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022; 81(6): 768-79. doi: 10.1136/annrheumdis-2021-221733. Epub 2022 Feb 2.
Vavlukis M, Pop-Gjorcevab D, Poposka L, Sandevska E, Kedev S. Myocardial Infarction in Systemic Lupus Erythematosus–the Sex-Specific Risk Profile. Curr Pharm Des. 2021; 27(29): 3221-8. doi: 10.2174/1381612826666201210110809.
Semalulu T, Tago A, Zhao K, Tselios K. Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the Clinician. Immunotargets Ther. 2023: 175-86. doi: 10.2147/ITT.S377076.
Garg S, Bartels CM, Bao G, Helmick CG, Drenkard C, Lim SS. Timing and Predictors of Incident Cardiovascular Disease in Systemic Lupus Erythematosus: Risk Occurs Early and Highlights Racial Disparities. J Rheumatol 2023; 50(1): 84-92. doi: 10.3899/jrheum.220279.
Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. Curr Vasc Pharmacol 2020; 18(6): 549-65. doi: 10.2174/1570161118666191227101636.
Bello N, Meyers KJ, Workman J, Hartley L, McMahon M. Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis. Lupus. 2023; 32(3): 325-41. doi: 10.1177/09612033221147471. Epub 2022 Dec 22.
Jha SB, Rivera AP, Monar GV, Islam H, Puttagunta SM, Islam R et al. Systemic lupus erythematosus and cardiovascular disease. Cureus. 2022; 14(2): e22027. doi: 10.7759/cureus.22027.
Li D, Yoshida K, Feldman CH, Speyer C, Barbhaiya M, Guan H et al. Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus. Rheumatology (Oxford). 2020; 59(3): 495-504. doi: 10.1093/rheumatology/kez288.
Gullo AL, Rodríguez-Carrio J, Gallizzi R, Imbalzano E, Squadrito G, Mandraffino G. Speckle tracking echocardiography as a new diagnostic tool for an assessment of cardiovascular disease in rheumatic patients. Prog Cardiovasc Dis. 2020; 63(3): 327-40. doi: 10.1016/j.pcad.2020.03.005. Epub 2020 Mar 20.
Zoccali C, Mark PB, Sarafidis P, Agarwal R, Adamczak M, Bueno de Oliveira R et al. Diagnosis of cardiovascular disease in patients with chronic kidney disease. Nat Rev Nephrol. 2023; 19(11): 733-46. doi: 10.1038/s41581-023-00747-4. Epub 2023 Aug 23.
Barber MR, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021; 17(9): 515-32. doi: 10.1038/s41584-021-00668-1. Epub 2021 Aug 3.
Aringer M, Johnson SR. Systemic lupus erythematosus classification and diagnosis. Rheum Dis Clin North Am. 2021; 47(3): 501-11. doi: 10.1016/j.rdc.2021.04.011. Epub 2021 Jun 10.
Johnson SR, Gladman DD, Brunner HI, Isenberg D, Clarke AE, Barber MR et al. Evaluating the construct of damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2023; 75(5): 998-1006. doi: 10.1002/acr.24849. Epub 2022 Dec 20.
Popescu BA, Stefanidis A, Fox KF, Cosyns B, Delgado V, Di Salvo GD et al. Training, competence, and quality improvement in echocardiography: the European Association of Cardiovascular Imaging Recommendations: update 2020. Eur Heart J Cardiovasc Imaging. 2020; 21(12): 1305-19. doi: 10.1093/ehjci/jeaa266.
Zhao LL, Takeuchi T, Avihingsanon Y, Yu XQ, Lapid EA, Lugue-Lizardo LR et al. Overview of Lupus Nephritis Management Guidelines and Perspective from Asia. Int J Rheum Dis. 2013; 16(6): 625-36. doi: 10.1111/1756-185X.12212. Epub 2013 Oct 31.
Zhang H, Yang C, Gao F, Hu S, Ma H. Evaluation of left ventricular systolic function in patients with systemic lupus erythematosus using ultrasonic layer-specific strain technology and its association with cardiovascular events: a long-term follow-up study. Cardiovasc Ultrasound 2022; 20: 25. doi:10.1186/s12947-022-00295-0.
Diaz?Gallo LM, Oke V, Lundström E, Elvin K, Ling Wu Y, Eketjäll S et al. Four systemic lupus erythematosus subgroups, defined by autoantibodies status, differ regarding HLA?DRB1 genotype associations and immunological and clinical manifestations. ACR Open Rheumatol. 2022; 4(1): 27-39. doi: 10.1002/acr2.11343. Epub 2021 Oct 17.
Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-García A. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep. 2021; 23(12): 85. doi: 10.1007/s11926-021-01038-2.
Leone P, Cicco S, Prete M, Solimando AG, Susca N, Crudele L et al. Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease. Clin Exp Med. 2020; 20(1): 11-19. doi: 10.1007/s10238-019-00600-8. Epub 2019 Dec 17.
Gegenava T, Gegenava M, Steup-Beekman GM, Huizinga TW, Bax JJ, Delgado V et al. Left ventricular systolic function in patients with systemic lupus erythematosus and its association with cardiovascular events. J Am Soc Echocardiogr. 2020; 33(9): 1116-22. doi: 10.1016/j.echo.2020.04.018. Epub 2020 Jul 1.
Hussain K, Gauto-Mariotti E, Cattoni HM, Arif AW, Richardson C, Manadan A et al. A meta-analysis and systematic review of valvular heart disease in systemic lupus erythematosus and its association with antiphospholipid antibodies. J Clin Rheumatol. 2021; 27(8): e525-32. doi: 10.1097/RHU.0000000000001464.
Ming Wang TK, Chan N, Khayata M. Cardiovascular Manifestations, Imaging, and Outcomes in Systemic Lupus Erythematosus: An Eight-Year Single Center Experience in the United States. Angiology. 2022; 73: 877-86. doi: 10.1177/00033197221078056.
Venturelli V, Abrantes AM, Rahman A, Isenberg DA. The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus. Rheumatology (Oxford). 2024; 63(SI): SI72-85. doi: 10.1093/rheumatology/kead618.
Liang H, Ma C, Chen X. Case report: Mitral valve replacement for Libman-Sacks endocarditis and cerebral embolism of primary antiphospholipid syndrome. Front Cardiovasc Med. 2022; 9: 985111. doi: 10.3389/fcvm.2022.985111.
Attuquayefio S, Doku A, Dey D, Agyekum F, Akumiah FK, Kweki AG et al. Cardiac Abnormalities in Relation to the Disease Activity Index Among Systemic Lupus Erythematosus Patients in a Tertiary Hospital: A Cross-Sectional Study. Cureus. 2023; 15(11): e49495. doi: 10.7759/cureus.49495.
Abdelrahman W, Sakr SA, Gohar N. Impact of antiphospholipid syndrome on disease characteristics and outcome in patients with systemic lupus erythematosus. Egypt Rheumatol. 2023: 67-72. doi: 10.1016/j.ejr.2022.11.002.
Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG et al. Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION International Clinical Database and Repository. Arthritis Care Res (Hoboken). 2022; 74(2): 324-35. doi: 10.1002/acr.24468.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Liaquat University of Medical & Health Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Submission of a manuscript to the journal implies that all authors have read and agreed to the content of the undertaking form or the Terms and Conditions.
When an article is accepted for publication, the author(s) retain the copyright and are required to grant the publisher the right of first publication and other non-exclusive publishing rights to JLUMHS.
Articles published in the Journal of Liaquat University of Medical & health sciences are open access articles under a Creative Commons Attribution-Noncommercial - Share Alike 4.0 License. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. This is in accordance with the BOAI definition of open access. In addition to that users are allowed to remix, tweak and build upon the work non-commercially as long as appropriate credit is given and the new creations are licensed under the identical terms. Or, in certain cases it can be stated that all articles and content there in are published under creative commons license unless stated otherwise.
